Second, the question regarding the use of native vitamin D in patients with CKD remains heavily debated, particularly with regard to the choice of compound, when to treat, and the most suitable dose to administer with or without VDR activators [15, 21–23] (Table 1). The gene discussed is VDR; the disease is chronic kidney disease.